- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Gammopathy.
Displaying page 1 of 2.
EudraCT Number: 2010-022693-14 | Sponsor Protocol Number: METc2010.214 | Start Date*: 2010-09-24 | ||||||||||||||||
Sponsor Name:university medical centre groningen | ||||||||||||||||||
Full Title: A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac) | ||||||||||||||||||
Medical condition: Monoclonal Gammopathy of Undetermined significance | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003865-11 | Sponsor Protocol Number: NEOD001-CL002 | Start Date*: 2015-11-27 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai... | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004318-14 | Sponsor Protocol Number: NEOD001-201 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005856-12 | Sponsor Protocol Number: 20221 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:Helsinki University Central Hospital | |||||||||||||
Full Title: Monoclonal gammopathies of renal significance (MGRS) in Finland | |||||||||||||
Medical condition: Rare renal diseases linked to monoclonal gammopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020072-33 | Sponsor Protocol Number: BVD-CLEM 01-10 | Start Date*: 2011-02-10 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | |||||||||||||
Full Title: Bendamustine, Bortezomib and Dexamethasone (BVD) in the treatment of relapsed or refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed or refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024156-28 | Sponsor Protocol Number: CACZ885DDE03T | Start Date*: 2011-05-16 | |||||||||||
Sponsor Name:Charité - University Hospital of Berlin | |||||||||||||
Full Title: A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome | |||||||||||||
Medical condition: Schnitzler syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021166-30 | Sponsor Protocol Number: 2010-SS-Canakinumab | Start Date*: 2010-11-25 |
Sponsor Name:Radboud University Nijmegen Medical Centre | ||
Full Title: Efficacy and safety of canakinumab in Schnitzler syndrome | ||
Medical condition: Schnitzler syndrome is an acquired autoinflammatory syndrome characterized by urticaria and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain and lymphade... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003835-20 | Sponsor Protocol Number: ALN-TTRSC-004 | Start Date*: 2014-11-26 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyl... | |||||||||||||
Medical condition: Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002637-15 | Sponsor Protocol Number: APL2-C3G-204 | Start Date*: 2020-12-22 |
Sponsor Name:Apellis Pharmaceuticals, Inc. | ||
Full Title: AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETACOPLAN IN THE TREATMENT OF POST-TRANSPLANT RECURRENCE OF C3G OR IC‑MPGN | ||
Medical condition: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing) NL (Ongoing) ES (Ongoing) FR (Completed) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004280-32 | Sponsor Protocol Number: AG10-301 | Start Date*: 2019-05-10 | |||||||||||
Sponsor Name:Eidos Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial) | |||||||||||||
Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) PT (Completed) ES (Ongoing) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004290-97 | Sponsor Protocol Number: ACCILTRA1 | Start Date*: 2008-12-19 |
Sponsor Name:Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy | ||
Full Title: A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzle... | ||
Medical condition: The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002655-33 | Sponsor Protocol Number: IEO S303/306 | Start Date*: 2006-07-25 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: Safety evaluation of the i.v. administration of Visipaque in patients with myeloma or monoclonal gammopathy | |||||||||||||
Medical condition: multiple myeloma, Waldenstrom disease o MGUS and lung cancer patients (control group | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004998-53 | Sponsor Protocol Number: OMB116024 | Start Date*: 2013-02-05 |
Sponsor Name:National and Kapodistrian University of Athens | ||
Full Title: A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia. | ||
Medical condition: Relapsed or refractory Waldenström’s Macroglobulinemia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000009-25 | Sponsor Protocol Number: 19PH226 | Start Date*: 2021-04-12 | |||||||||||
Sponsor Name:CHU SAINT-ETIENNE | |||||||||||||
Full Title: Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study | |||||||||||||
Medical condition: Anti-MAG neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002585-33 | Sponsor Protocol Number: PETAL | Start Date*: 2023-01-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) | ||||||||||||||||||
Medical condition: cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002639-48 | Sponsor Protocol Number: 54767414AMY2009 | Start Date*: 2022-07-25 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis | |||||||||||||
Medical condition: Amyloid Light Chain Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) IT (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001458-24 | Sponsor Protocol Number: ALN-TTR02-011 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (... | |||||||||||||
Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) DK (Ongoing) BG (Completed) PT (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005557-73 | Sponsor Protocol Number: I10E-1302 | Start Date*: 2014-10-21 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000067-23 | Sponsor Protocol Number: PN-1007-001 | Start Date*: 2020-09-21 | |||||||||||
Sponsor Name:Polyneuron Pharmaceuticals AG | |||||||||||||
Full Title: First in Human Study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PPSGG in anti-MAG neuropathy patients | |||||||||||||
Medical condition: anti-MAG neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002465-35 | Sponsor Protocol Number: B3461028 | Start Date*: 2014-04-07 | |||||||||||
Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company | |||||||||||||
Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.